Myriad Genetics INC Form 4 insider transactions

Paul J. Diaz, President and CEO of Myriad Genetics, sold 15,000 shares of common stock on October 11, 2024, at a price of $22.93 per share.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, sold 452 shares to cover tax obligations related to vesting restricted stock units.

Chief Technology Officer Kevin Richard Haas of Myriad Genetics Inc. reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, sold 1,075 shares to cover tax obligations related to vesting restricted stock units.

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, disposed of 966 shares of common stock on September 21, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of 964 shares to cover tax obligations related to vesting restricted stock units.

Myriad Genetics CEO Paul J. Diaz sold 15,000 shares of common stock at a price of $26.72 per share on September 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, sold 2,100 shares of common stock on September 11, 2024, at a price of $26.172 per share.

Director Heinrich Dreismann sold 10,000 shares of Myriad Genetics Inc. on September 9, 2024, at an average price of $27.052 per share.

Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics, reports the acquisition of 61,771 restricted stock units.

Director Colleen F. Reitan sold 4,6012 shares of Myriad Genetics Inc. common stock at a weighted average price of $27.946 per share on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of 217 common stock shares to cover tax obligations related to vesting restricted stock units.

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, sold 11,538 shares of common stock at $27.82 per share on August 21, 2024.

Director Rashmi Kumar sold 7,500 shares of Myriad Genetics Inc. on August 19, 2024, at a price of $28.01 per share, according to a Form 4 filing.

Paul J. Diaz, President and CEO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Director Daniel Skovronsky reports acquisition of Myriad Genetics restricted stock units.

Director Heinrich Dreismann reports acquisition of restricted stock units in Myriad Genetics, Inc.

Director Lee Nisley Newcomer reports acquiring and disposing of Myriad Genetics common stock, including restricted stock units, in a recent transaction.

Director Rashmi Kumar reported the acquisition of 15,695 restricted stock units in Myriad Genetics, Inc.

Director Colleen F. Reitan reported acquiring 15,695 shares of Myriad Genetics Inc. common stock and disposing of shares, resulting in a total beneficial ownership of 88,545 shares.

Director S. Louise Phanstiel reports the acquisition of Myriad Genetics (MYGN) stock and restricted stock units.

Director Paul Bisaro reports acquisition of restricted stock units and disposal of common stock.

Daniel K. Spiegelman, a director at Myriad Genetics, filed a Form 4 with the SEC to report his departure from the company, effective June 6, 2024.

Director Daniel K. Spiegelman of Myriad Genetics sold a portion of his common stock holdings on June 3rd and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Paul J. Diaz, President and CEO of Myriad Genetics, sold a significant number of shares of common stock over three days in May 2024.

Director Lee Nisley Newcomer of Myriad Genetics Inc. sold 6,200 shares of common stock at an average price of $25.30 on May 13, 2024.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, disposed of shares to cover tax obligations related to vesting restricted stock units.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of 1,076 common stock shares to cover tax obligations related to vesting restricted stock units.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.